If the CC includes more commentary from ongoing positive CX-717 discussions with the FDA, then the IND would be more of a formality, and we would have more closure on the ADHD dosing concerns. That I can live with.
You're low odds of a partnership is disappointing, though. Is that because it will most likely be inked after the IND is approved?
BTW, chances are good we will get a bounce tomorrow since Gfp unloaded some shares.